Related Experiment Video
Updated: May 24, 2026
06:06
Color Spot Test As a Presumptive Tool for the Rapid Detection of Synthetic Cathinones
Published on: February 5, 2018
CpG still rocks! Update on an accidental drug
1RaNA Therapeutics, Inc., Cambridge, Massachusetts 02141, USA. cpgrocks@gmail.com
Nucleic Acid Therapeutics
|February 23, 2012
Summary
The discovery of CpG motifs revolutionized understanding of oligodeoxynucleotides (ODN) immune effects. Clinical trials show CpG ODN
Area of Science:
- Immunology
- Pharmacology
- Molecular Biology
Background:
- The discovery of CpG motifs in 1995 revealed the immune-stimulatory potential of oligodeoxynucleotides (ODN).
- Initially viewed as a nonspecific effect, CpG ODN's immune activation is now recognized as an evolved defense mechanism.
- This understanding opened avenues for therapeutic applications targeting the immune system.
Purpose of the Study:
- To review the clinical development of CpG ODN.
- To summarize results from human clinical trials involving CpG ODN.
- To provide an overview of therapeutic applications and limitations.
Main Methods:
- Literature review of clinical trials and studies on CpG ODN.
- Analysis of data from human clinical trials for various applications.
- Synthesis of findings regarding efficacy and limitations of CpG ODN therapies.
Main Results:
- Dozens of human clinical trials have been conducted with various CpG ODN formulations.
- Applications explored include vaccine adjuvants, and immunotherapies for allergy, cancer, and infectious diseases.
- While many positive outcomes were observed, some trials failed, highlighting therapeutic limitations.
Conclusions:
- CpG ODN have demonstrated significant potential in diverse therapeutic areas.
- Clinical development has revealed both successes and limitations of current CpG ODN approaches.
- Further research is needed to optimize CpG ODN therapies and overcome existing challenges.
Related Concept Videos
01:19Pharmacovigilance
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
01:25Drug Regulation
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
01:26Pharmaceutical Poisoning: Potential Scenarios
Pharmaceutical poisoning can occur through various channels, impacting an estimated 2 million hospitalized patients in the U.S. annually with serious adverse drug responses. These scenarios encompass both therapeutic uses, such as drug toxicity, where even standard dosages can lead to severe central nervous system depression, and non-therapeutic exposures, including accidental ingestion by children, and environmental and occupational exposures.Unintentional poisonings often involve exploratory...
01:16Drug Biotransformation: Overview
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
01:28Drug Biotransformation: Overview
Biotransformation, also known as drug metabolism, is a vital physiological process that chemically alters drugs, facilitating their elimination from the body and terminating their action. This process involves two main phases: phase I and phase II reactions. Phase I reactions, including oxidation, reduction, and hydrolysis, introduce or unmask polar functional groups on the drug molecule, thereby increasing its water solubility. By enhancing water solubility, the drug becomes more hydrophilic...
01:17Drug Metabolism: Phase I Reactions
A phase I reaction is a biochemical process that introduces a functionally reactive polar group to a substance. This transformation predominantly occurs in the liver, facilitated by the cytochrome P450 system of hemoproteins situated in the lipophilic endoplasmic reticulum of cells. The metabolite generated through this process can have varying polarities. If it is sufficiently polar, it can be easily excreted in the urine due to its water compatibility. However, if the metabolite is nonpolar,...